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Abstract
Glucokinase (GCK) is an enzyme that regulates insulin secretion,
keeping glucose levels within a narrow range. Mutations in the
glucokinase gene cause a rare form of diabetes called maturity-onset
diabetes of the young (MODY). An early onset (less than 25 years),
autosomal dominant inheritance and low insulin secretion stimulated
by glucose characterize MODY patients. Specific insulin and proinsu-
lin were measured in serum by immunofluorimetric assays (IFMA)
during a 75-g oral glucose tolerance test (OGTT). Two kindreds (SA
and LZ) were studied and compared to non-diabetic unrelated indi-
viduals (control group 1) matched for age and body mass index (BMI).
In one kindred, some of these subjects were also obese (BMI >26 kg/
m2), and other family members also presented with obesity and/or late-
onset NIDDM. The MODY patients were also compared to a group of
five of their first-degree relatives with obesity and/or late-onset NIDDM.
The proinsulin profile was different in members of the two MODY
kindreds. Fasting proinsulin and the proinsulin/insulin ratio were
similar in MODY members of kindred LZ and subjects from control
group 1, but were significantly lower than in MODY members of
kindred SA (P<0.02 and P<0.01, for proinsulin and proinsulin/insulin
ratio, respectively). Moreover, MODY members of family SA had
higher levels of proinsulin and proinsulin/insulin ratio, although not
significantly different, when compared to their first-degree relatives
and to subjects from control group 2. In conclusion, we observed
variable degrees of proinsulin levels and proinsulin/insulin ratio in
MODY members of two different kindreds. The higher values of these
parameters found in MODY and non-MODY members of kindred SA
is probably related to the obesity and late-onset NIDDM background
present in this family.
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Introduction
Maturity-onset diabetes of the young
(MODY) is a genetically heterogeneous syn-
drome that can be caused by heterozygous
mutations in the glucokinase (GCK) gene in
approximately 50% of MODY cases in
France (1). This form is characterized by an
early onset (<25 years old) of diabetes melli-
tus, mild hyperglycemia and autosomal domi-
nant inheritance (1). Mutations in the GCK
gene cause impaired insulin secretion in re-
sponse to glucose (2), a reduction in post-
prandial hepatic glycogen synthesis and an
increased rate of gluconeogenesis after
meals (3).
Proinsulin, the precursor of insulin, is
biologically less active than insulin and an
increased secretion of these molecules is
considered to reflect ß-cell dysfunction (4,5).
A disproportionate increase of proinsulin
and its conversion intermediates, and an in-
creasing proinsulin-to-insulin ratio are asso-
ciated with insulin resistance syndrome (6,7).
Patients with increased insulin secretion with-
out hyperglycemia, such as obesity, present
hyperproinsulinemia without an increase in
the proinsulin-to-insulin ratio (7). Proinsulin
levels have not been extensively studied in
glucokinase-deficient subjects. We report
here the assessment of specific insulin and
proinsulin in members of two Brazilian glu-
cokinase-deficient MODY families.
Material and Methods
Individuals
We studied two MODY families (LZ and
SA) with different mutations in the GCK
gene. In the LZ kindred the E248X mutation
was found in the proband and three of his
sons with MODY (8). These patients were
compared to six non-diabetic unrelated indi-
viduals (control group 1) matched for age
and body mass index (BMI). In the SA kin-
dred the V401del1 mutation was detected in
6 subjects with MODY (8). Some of these
subjects were also obese (BMI >26 kg/m2),
and other family members also presented
with obesity and/or late-onset non-insulin-
dependent diabetes (NIDDM). The MODY
patients were compared to a group of five of
their first-degree relatives with obesity and/
or late-onset NIDDM, and to eleven non-
diabetic unrelated individuals (control group
2) matched by age and BMI.
The patients blood glucose was con-
trolled only by diet and they were not using
any drug. Normal glucose tolerance (NGT),
impaired fasting glucose (IGT) and diabetes
mellitus (DM) were defined according to the
new diagnosis and classification of diabetes
mellitus by the Expert Committee Report
(9). The control group consisted of outpa-
tients seen at the Endocrinology Division of
the Universidade Federal de Sªo Paulo who
showed NGT after the oral glucose tolerance
test (OGTT). All individuals and patients
gave informed consent to take part in the
study. The study was approved by the Uni-
versity Ethics committee.
Analytical methods
All individuals underwent an OGTT af-
ter a 10-h fast and blood samples were col-
lected at 0, 30, 60 and 120 min after 75 g
glucose ingestion for plasma glucose, serum
insulin and proinsulin measurement. Glu-
cose was assayed by the glucose oxidase
method. Serum insulin and proinsulin were
measured by an immunofluorimetric assay.
These assays detect 100% human insulin
and proinsulin, respectively, and both show
100% cross-reactivity with 64,65 proinsulin
and split 65,66 proinsulin and no cross-reac-
tivity with des 31,32 proinsulin or split 32,33
proinsulin. Beta-cell function in response to
the oral ingestion of 75 g glucose was quan-
tified as the ratio of the incremental plasma
insulin response (RIR) above basal levels at
30 min to that of plasma glucose, divided by
basal plasma insulin levels ([D30-0-min in-
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sulin/D30-0-min glucose]/basal insulin) (10).
Statistical analysis
Data are reported as mean – SD, unless
otherwise stated. Non-parametric tests were
performed. The Mann-Whitney U and the
Kruskal-Wallis tests were used when com-
paring two or three groups, respectively.
Quantitative traits were compared by analy-
sis of variance (ANOVA). When ANOVA
was significant, comparisons between pairs
were made by the Tukey-Kramer HSD test
(11). Data were analyzed using the Statisti-
cal Package for Social Science for Windows,
version 7.0 (SPSS Inc., Chicago, IL). A P
value less than 0.05 was considered statisti-
cally significant.
Results
The clinical and metabolic profiles of
family members and control groups are
shown in Table 1. The relative insulin re-
sponse (RIR) was significantly decreased in
MODY members of kindred LZ as com-
pared to control group 1, as expected (2).
RIR was significantly decreased both in
MODY members and in the first-degree rela-
tives of kindred SA compared to control
group 2. The proinsulin profile was different
in members of the two MODY kindreds.
Fasting proinsulin and the proinsulin/insulin
ratio were similar in MODY members of
kindred LZ and subjects from control group
1, but were significantly lower when com-
pared to those of MODY members of kin-
dred SA (P<0.02 and P<0.01 for proinsulin
and proinsulin/insulin ratio, respectively).
Moreover, MODY members of family SA
had higher levels of proinsulin and a higher
proinsulin/insulin ratio, although not signif-
icantly different, when compared to their
first-degree relatives and to subjects from
control group 2.
Stepwise multiple regression analysis was
performed with proinsulin or the proinsulin/
insulin ratio as the dependent variable and
sex, age, BMI, glucokinase mutation status,
fasting and 2-h glucose, fasting insulin and
RIR as independent variables. Data were
log-transformed and all subjects were in-
cluded in the analysis. The BMI and RIR
(inverse correlation) accounted for 53%
Table 1 - Clinical and metabolic profiles of family members.
Data are reported as mean and interquartile range. The Kruskal-Wallis (rank sums) and Tukey-Kramer HSD tests with log-transformed data were
used when the results of the Kruskal-Wallis test were significant (P<0.05). #P<0.05 compared to control group 2, and *P<0.05 compared to
unaffected relatives. a[D30-0-min insulin/D30-0-min glucose]/basal insulin. W, Women; M, men.
Kindred LZ Control group 1  P Kindred SA Control group 2 First-degree  P
(MODY subjects) (MODY subjects) relatives
Subjects/sex (N) 4 (0 W/4 M) 6 (3 W/3 M) - 6 (3 W/3 M) 11 (5 W/6 M) 5 (3 W/2 M) -
Age (years) 21 (10-37) 27 (25-30) 0.24 21 (16-26)* 26 (23-31) 37 (29-47) <0.02
BMI (kg/m2) 19.8 (16.4-23.5) 22.0 (18.0-24.3) 0.34 26.5 (24.0-30.4) 27.8 (24.0-30.0) 27.9 (23.7-32.6) 0.97
Fasting glucose (mmol/l) 6.3 (5.4-6.7) 4.7 (3.4-5.3) <0.02 6.8 (6.5-7.3)#* 5.1 (4.7-5.2) 4.8 (4.2-5.4) <0.003
Fasting insulin (pmol/l) 18 (12-22) 39 (15-62) 0.20 39 (15-68) 35 (15-41) 47 (28-65) 0.45
Fasting proinsulin (pmol/l) 0.23 (0.10-0.48) 0.63 (0.10-1.20) 0.40 5.10 (2.45-7.78) 2.65 (0.4-4.2) 5.22 (1.55-9.85) 0.19
Fasting proinsulin/insulin (%) 1.6 (0.5-3.8) 1.1 (0.6-1.8) 0.59 17.7 (5.6-28.7) 9.5 (2.7-12.7) 10.5 (4.1-18.8) 0.43
2-h glucose (mmol/l) 10.3 (8.0-13.7) 4.4 (3.1-5.2) <0.02 9.8 (7.3-13.1)# 5.5 (4.5-6.7) 7.7 (5.6-10.7) <0.04
2-h insulin (pmol/l) 35 (8-69) 180 (64-297) <0.03 174 (91-252) 161 (36-180) 155 (50-285) 0.61
2-h proinsulin (pmol/l) 9.2 (3.8-14.7) 12.5 (6.4-19.7) 0.46 30.1 (22.4-36.5) 19.3 (6.5-35.5) 22.7 (16.0-29.4) 0.22
Relative insulin response 0.71 (0.12-1.60) 3.61 (1.70-4.76) <0.04 1.04 (0.10-1.58)# 3.28 (1.10-5.17) 0.60 (0.26-1.00)# <0.04
(l/mmol)a
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(P<0.0001) and 8% (P<0.02) proinsulin vari-
ance, respectively. Moreover, BMI, fasting
insulin (inverse correlation), the presence of
a glucokinase mutation, and the sex (women)
accounted for 24% (P<0.0002), 13%
(P<0.004), 8% (P<0.04) and 7% (P<0.05),
respectively, of the variance of proinsulin/
insulin ratio in these subjects.
Discussion
Many reports have shown that GCK-de-
ficient patients have a reduced early insulin
response after a glucose load (1,4,12). In the
present study we found abnormal ß-cell func-
tion in GCK-deficient individuals, even in
the family with NIDDM patients (pedigree
SA). In this family the proinsulin levels were
increased maybe as a consequence of the
stimulation of ß-cells to release immature
granules (5). An increased proinsulin/insu-
lin ratio can be observed in individuals with
an NIDDM background (6). Patients from
pedigree SA showed a trend towards high
values for this ratio maybe as a consequence
of their NIDDM background.
We found here a failure of insulin release
after a glucose stimulus in GCK-deficient
individuals. GCK-deficient individuals
showed normal levels of proinsulin but when
obesity was also present, ß-cells secreted
more proinsulin. The proinsulin levels were
increased in obese patients in spite of the
low activity of the GCK enzyme. These re-
sults are in agreement with those of Hattersley
and co-workers (13), showing normal proin-
sulin levels and proinsulin/insulin ratio in
lean MODY subjects.
In conclusion, we observed variable de-
grees of proinsulin levels and proinsulin/
insulin ratio in MODY members of two dif-
ferent kindreds. The higher values of these
parameters found in MODY and non-MODY
members of kindred SA are probably related
to the obesity and late-onset NIDDM back-
ground present in this family. The BMI was
the most important independent determinant
of high proinsulin levels and proinsulin/in-
sulin ratio in these subjects.
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